| |
At the international exhibition "Healthcare – TIHE 2009" that took place in Tashkent provisional agreements were made between the domestic manufacturer Pharmaco Group, and regional distributors, the company informs.
"The medical forum enabled the company to show itself to be the new Central Asian manufacturer of high quality medications. The level and size of the exhibition – which resulted in hundreds of contracts being signed each day - allowed us to reach all of our set goals. We carried out the analysis of Uzbekistan’s pharmaceutical market, met the leading medical professionals and representatives of distributing companies. Presently we are to choose an exclusive partner to represent us in Uzbekistan, register and distribute Pharmaco Group products in the republic", says Alexander Karpov, Pharmaco Group General Director, as quoted by the company press office.
According to A. Karpov, “Pharmaco Group products generated considerable interest among distributors and doctors due to their good value for money; particular attention was drawn to the antibiotic group manufactured at the Bishkek facility, particularly cefazolin, which currently is a sought-for medication in the Uzbek pharmaceutical market”.
“Considering the fact that Uzbekistan is the most densely populated country in Central Asia, the pharmaceutical market of the republic has very promising prospects for Pharmaco Group. On the other hand, as it turned out, the neighboring state was in need of generic medications. We have already begun working on forming the product mix proposal,” notes the head of the company, as quoted by the press office.
Pharmaco Group is a pharmaceutical plant located in Bishkek, the Kyrgyz capital. Its annual output equals 500 million pills, 100 million capsules and 12 million vials of antibiotic powders. These medications are used in gastroenterology, dermatology, gynecology, urology, rheumatology, cardiology and pediatrics.
The strategic goal of Pharmaco Group is to boost its export potential in Central Asia (Uzbekistan, Tajikistan and Afghanistan). By the end of 2009 the facility will launch production of six antituberculous drugs - capreomicin, pyrazinamide, cycloserine, paraaminosalicylic acid, protionamide and ofloxacin. In the nearest future Pharmaco Group is planning to introduce antidiabetic medications such as gliclazide and metformin to its product portfolio.
"Healthcare – TIHE 2009" is the annual Central Asian exhibition project. In 2009 it was held for the fourteenth time and included four specialized medical exhibitions devoted to healthcare, pharmaceutical industry, aesthetic medicine and dentistry. Companies from Russia, China, USA, Great Britain, Switzerland, Turkey South Korea and the Central Asian countries are among the participants and attendees of the event.
MGN Analysis
Pharmaco Group, a pharmaceutical manufacture, which began operating in 2008 and is headquartered in Bishkek Kyrgyzstan, announced that it is expanding to other Central Asia markets. The company, which produces various generic and specialty drugs in pill, capsule and vial form, has been aggressively growing in the Kyrgyz market and is now seeking to expand in neighboring markets. The pharmaceutical market in Kyrgyzstan and neighbor countries is estimated in excess of $1.0 bln UDS. MGN anticipated Pharmaco’s ability to grow to external markets as the company is known to produce high quality pharmaceutical products in Kyrgyzstan. MGN believes that this is just the first in a series of success stories to come from this company. We anticipate that Pharmaco Group will boldly compete with other pharmacy companies in Central Asia and is a highlight in the Kyrgyz business community.
|
Sophya.balakina[.]flexicommunications.com 
